Zentalis Pharmaceuticals, Inc. (ZNTL)
NGM · Healthcare · Biotechnology
Closing price as of 2026-06-08 · Source: TEK2day Finance
Key Metrics
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -36.1M | -33.7M | -37.4M | -37.9M |
| Net Income | -26.9M | -26.7M | -35.2M | -35.4M |
| Diluted EPS | $-0.37 | $-0.37 | $nan | $-0.50 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 67.4M | 0.00 |
| Operating Income | -227.3M | -253.9M | -187.5M | -145.0M |
| Net Income | -236.8M | -292.2M | -165.8M | -137.1M |
| Diluted EPS | $-4.48 | $-4.47 | $-2.33 | $nan |